C₁₇H₁₅N₅O₇P^.Na; MW 455.3; λ_max 279 nm; ε 17000; sodium salt; purity > 98% HPLC, highly purified. For other salt forms or metabolites of 6-Bnz-cAMP please inquire. Site-selective and membrane-permeant activator of cAMP-dependent protein kinase (cAK) which does not activate Epac and thus can be used as an Epac-negative control. Increased metabolic stability against PDE compared to cAMP. Selects site A of both cAK isozymes and thus can be used for synergistic activation of type II when combined with site B II- selective analogues such as Sp-8-CPT-cAMPS (Cat. No. C 012) or 8-PIP-cAMP (Cat. No. P 002). For preferential stimulation of cAK type I a combination with the site B I-selective analogue 2-Cl-8-MA-cAMP (Cat. No. C 080) or 8-HA-cAMP (Cat. No. H 006) can be used. For more details on site selectivity please inquire. Detailed technical information and updated reference list available. References: Døskeland et al., Biochim. Biophys. Acta, 1178, 249 - 258 (1993); Christensen et al., J. Biol. Chem., 278, 35394 - 35402 (2003); Bos, Trends Biochem. Sci., 31, 680 - 686 (2006). The corresponding PDE-stable form Sp-6-Bnz-cAMPS (Cat. No. B 040) is available as well.